A Phase 1/2a Study of BMS-986253 in Combination with Nivolumab in Advanced Cancers
Study of BMS-986253 in Combination with Nivolumab in Advanced Cancers
Sponsor: Bristol-Myers Squibb
Enrolling: Male and Female Patients
IRB Number: AAAR6272
U.S. Govt. ID: NCT03400332
Contact: Research Nurse Navigator: 212-342-5162 / cancerclinicaltrials@cumc.columbia.edu
Additional Study Information: The purpose of this study is to explore how the combination of the study drugs affects tumors and general health. The study drugs are BMS-986253 and nivolumab. Participants will be given different doses of BMS-986253 and nivolumab to test how safe they are in humans. This is the first study in which BMS-986253 is being given in combination with nivolumab.
This study is closed
Investigator
Brian Henick, MD
Do You Qualify?
Do you have a solid tumor that continues to spread, has come back, or cannot be removed completely by surgery? Yes No
Are you willing to have a pre-treatment and on-treatment biopsy? Yes No
Are you able to walk, care for yourself, and do light physical activities? Yes No
Submit
Cancel
You may be eligible for this study

Place Holder



Cancel
For more information, please contact:
Research Nurse Navigator
cancerclinicaltrials@cumc.columbia.edu
212-342-5162
This website uses cookies as well as similar tools and technologies to understand visitors’ experiences. By continuing to use this website, you consent to Columbia University’s usage of cookies and similar technologies, in accordance with the Columbia University Website Cookie Notice.
I AGREE